Back

Effects of Chios Mastiha essential oil on cholesterol levels of healthy volunteers: a prospective, randomized, placebo-controlled study.

31 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Lipoproteins and cardiovascular risk Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Dimitrios Afendoulis

Hippokration General Hospital, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Sex-specific guideline target value attainment and prognostic value of low-density lipoprotein cholesterol in tertiary care
Ms K. Rumora (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Circulating Amyloid beta 1-40 is independently associated with statin treatment and LDL cholesterol reduction: a prospective cohort study
Doctor E. Aivalioti (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Factors influencing low-density-lipoprotein cholesterol after acute coronary syndrome and effectiveness of intensive teleconsultation monitoring, the teleobjectif cohort study
Doctor A. Lemaitre (Caen, FR)
Abstract Slides Video
Presentation thumbnail
Remnant cholesterol, clinical characteristics and mortality in 41.767 patients from LIPIDOGRAM 2004-2015 studies - the factor analysis for mixed data cluster analysis
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Relationship of cumulative low-density lipoprotein cholesterol with atherosclerosis
Doctor T. Yamaji (Hiroshima, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Lipoproteins and cardiovascular risk

The Event

Event poster

ESC Congress 2024

31 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy
thumbnail
Congress Presentation
Phase 1 trial of a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex in patients with mixed hyperlipidaemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources